IQVIA is currently looking for individuals with wet age-related macular degeneration (wet AMD) or diabetic macular edema (DME) who are being treated with EYLEA HD® to take part in a 60-minute telephone interview. To thank you for your time and effort, you will be compensated $200 following completion of your interview ($150 for your time completing the [Read More]
The Prevent Blindness government affairs team has been notified of a potential opportunity to share your story with lawmakers about the harmful impact of “step therapy.” We understand that, in an effort to pass the Safe Step Act into law, legislators want to hear patient stories that will help compel action on this important bill. [Read More]
Genentech has received FDA approval of Vabysmo® for the treatment of macular edema due to retinal vein occlusion (RVO) beyond six months. RVO affects over a million Americans and often involves long-term intravitreal therapy to address the chronic nature of the disease. “This label update reinforces our commitment to delivering consistent, long-term solutions for patients [Read More]